GlassScriptPhysician profile
Eimile Dalton-Fitzgerald
NPI 1801156088
$11,104.21
in general payments reported to CMS, 2019-2025
41 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,384 · 2020: $1,157 · 2021: $1,950 · 2022: $1,762 · 2023: $1,379 · 2024: $1,850 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,835 · Education: $15.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,835.17 |
| Education | $15.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,846.57 | 2019-2025 | Rinvoq, Mavyret, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,664.71 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Pfizer INC. | $575.17 | 2021-2025 | |
| Romark Laboratories, Lc | $574.24 | 2019-2020 | |
| Celgene Corporation | $541.50 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $488.04 | 2019-2025 | Tremfya, Stelara, Remicade |
| Janssen Scientific Affairs, LLC | $363.17 | 2019-2025 | Tremfya |
| Genzyme Corporation | $282.34 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $254.63 | 2019-2024 | Gattex |
| Qol Medical, LLC | $179.45 | 2019-2025 | Sucraid |
| Ardelyx, INC. | $170.38 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $168.29 | 2020-2023 | |
| Gilead Sciences, INC. | $151.50 | 2019-2023 | |
| Conmed Corporation | $145.83 | 2021 | |
| Intuitive Surgical, INC. | $145.40 | 2023 | Da Vinci Surgical System |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $138.13 | 2024-2025 | Vegzelma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $131.15 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $106.23 | 2024-2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $95.00 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $94.53 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $91.95 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Daiichi Sankyo INC. | $82.90 | 2019-2022 | |
| Braintree Laboratories, INC. | $81.89 | 2019-2023 | Sutab |
| Ucb, INC. | $81.63 | 2019-2021 | |
| Boston Scientific Corporation | $76.11 | 2021 | |
| Ethicon US, LLC | $75.21 | 2019 | |
| Lumendi LLC | $68.36 | 2021 | |
| Merck Sharp & Dohme LLC | $62.79 | 2019-2023 | Dificid |
| Lilly USA, LLC | $61.46 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $45.67 | 2021 | |
| Phathom Pharmaceuticals, INC. | $43.45 | 2024 | Voquezna |
| Covidien LP | $41.67 | 2019 | |
| Alfasigma USA, INC. | $27.58 | 2020 | |
| Sandoz INC. | $25.18 | 2023 | Hyrimoz |
| Shire North American Group INC | $23.63 | 2019 | |
| Allergan, INC. | $22.47 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.02 | 2024 | Cyltezo |
| Organon LLC | $21.21 | 2025 | Hadlima |
| Vivus LLC | $19.59 | 2024 | Qsymia |
| Ferring Pharmaceuticals INC. | $13.18 | 2023 | Rebyota |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,796.47 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eimile Dalton-Fitzgerald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.